PSTX — Poseida Therapeutics Share Price
Last trade - 00:00- $927.88m
- $755.94m
- $64.70m
- 30
- 13
- 90
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.64 | ||
| Price to Tang. Book | 11.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.15 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -29.03% | ||
| Return on Equity | -57.63% | ||
| Operating Margin | -41.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 31.24 | 130.49 | 64.7 | 147.12 | 43.33 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.
Directors
- Eric Ostertag CHM (48)
- Mark Gergen PRE (59)
- Johanna Mylet CFO (34)
- Kerry Ingalls COO (59)
- Kristin Martin CHO
- Devon Shedlock CSO
- Harry Leonhardt CCO (64)
- Matthew Spear OTH (54)
- Cynthia Collins DRC (63)
- Luke Corning IND (39)
- David Hirsch IND (50)
- Marcea Lloyd IND (72)
- John Schmid IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- December 16th, 2014
- Public Since
- July 10th, 2020
- No. of Shareholders
- 64
- No. of Employees
- 350
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 97,466,666
- Address
- 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO, 92121
- Web
- https://poseida.com/
- Phone
- +1 8587793100
- Contact
- Alex Lobo
- Auditors
- PricewaterhouseCoopers LLP
Latest News for PSTX
Upcoming Events for PSTX
Q4 2024 Poseida Therapeutics Inc Earnings Release
Q1 2025 Poseida Therapeutics Inc Earnings Release
Poseida Therapeutics Inc Annual Shareholders Meeting
Similar to PSTX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 21:41 UTC, shares in Poseida Therapeutics are trading at $9.52. This share price information is delayed by 15 minutes.
Shares in Poseida Therapeutics last closed at $9.52 and the price had moved by +195.65% over the past 365 days. In terms of relative price strength the Poseida Therapeutics share price has outperformed the S&P500 Index by +133.7% over the past year.
The overall consensus recommendation for Poseida Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePoseida Therapeutics does not currently pay a dividend.
Poseida Therapeutics does not currently pay a dividend.
Poseida Therapeutics does not currently pay a dividend.
To buy shares in Poseida Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $9.52, shares in Poseida Therapeutics had a market capitalisation of $927.88m.
Here are the trading details for Poseida Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PSTX
Based on an overall assessment of its quality, value and momentum Poseida Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Poseida Therapeutics is $9.00. That is 5.46% below the last closing price of $9.52.
Analysts covering Poseida Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.95 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Poseida Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +199.59%.
As of the last closing price of $9.52, shares in Poseida Therapeutics were trading +155.75% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Poseida Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.52.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Poseida Therapeutics' management team is headed by:
- Eric Ostertag - CHM
- Mark Gergen - PRE
- Johanna Mylet - CFO
- Kerry Ingalls - COO
- Kristin Martin - CHO
- Devon Shedlock - CSO
- Harry Leonhardt - CCO
- Matthew Spear - OTH
- Cynthia Collins - DRC
- Luke Corning - IND
- David Hirsch - IND
- Marcea Lloyd - IND
- John Schmid - IND